Chorionic Gonadotropin (Human)
- Atc Codes:G03GA01
- CAS Codes:9002-61-3
- PHARMGKB ID:9002-61-3
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Pregnyl; Belgium: Choragon, Pregnyl; Bulgaria: Pregnyl; Cyprus: Choriomon, Pregnyl; Czech Republic: Pregnyl; Denmark: Pregnyl; Estonia: Pregnyl; Finland: Pregnyl; France: Gonadothrophine Chorionique Endo; Germany: Brevactid, Choragon; Hungary: Choragon, Pregnyl; Ireland: Pregnyl; Italy: Gonasi HP, Pregnyl; Latvia: Pregnyl; Lithuania: Pregnyl; Luxembourg: Pregnyl; Netherlands: Choragon, Pregnyl; Poland: Choragon, Pregnyl, Profasi; Portugal: Pregnyl; Romania: Pregnyl; Slovakia: Choragon, Pregnyl; Spain: HCG-Lepori; Sweden: Pregnyl; UK: Choragon, Pregnyl.
North America
Canada: Pregnyl; USA: Pregnyl.
Latin America
Argentina: Endocorion, Gonacor, Pregnyl; Brazil: Pregnyl, Profasi HP; Mexico: Choragon, Choriomon, Gonakor, Pregnyl.
Asia
Japan: Gestoron, Gonatropin, Pregnyl, Profasi.
Drug combinations
Chemistry
Gonadotropin, Chorionic: CAS-9002-61-3.
Pharmacologic Category
Gonadotropins. Ovulation Stimulator. (ATC-Code: G03GA01).
Mechanism of action
Human chorionic gonadotropin, a glycoprotein heterodimer, derives from syncytiotrophoblastic cells, and is obtained from the urine of pregnant women. Stimulates production of gonadal steroid hormones. In pregnancy, it stimulates progesterone secretion by the corpus luteum, which maintains secretory endometrium and also promotes trophoblastic differentiation. It is a marker for trophoblastic tumors, including hydatidiform mole and choriocarcinoma.
Therapeutic use
Induces ovulation and pregnancy in anovulatory, infertile females. Hypogonadotropic hypogonadism, prepubertal cryptorchidism. Spermatogenesis induction with follitropin alpha.
Pregnancy and lactiation implications
Teratogenic effects (forelimb, CNS) noted in animal studies at doses intended to induce superovulation (used in combination with gonadotropin). Testicular tumors in otherwise healthy men reported when treating secondary infertility. Excretion in breast milk unknown (use caution).
Unlabeled use
Contraindications
Hypersensitivity to chorionic gonadotropin or any component of the formulation. Precocious puberty. Prostatic carcinoma or similar neoplasms. Pregnancy.
Warnings and precautions
Use with caution in the following cases: asthma, cardiovascular disease, history of migraines, renal impairment, or history of seizure disorders. May induce precocious puberty in children being treated for cryptorchidism. Not effective in the treatment of obesity. May cause ovarian hyperstimulation syndrome. Thromboembolic events reported. Risk of multiple births.